OABI - NASDAQ
OmniAb, Inc.
$2.69
+2.9%OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
At a Glance
Live SnapshotOmniAb, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
OmniAb, Inc. Income Statement
OABI • NASDAQ
| OmniAb, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
18.7M | 26.4M | 34.2M | 59.1M | 34.7M | 23.3M | 18.3M | |
GROSS PROFIT | |||||||
(22.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-3.4M | 26.4M | 34.2M | 59.1M | 34.7M | 23.3M | 18.3M | |
OPERATING INCOME | |||||||
(68.1M) | (100.9M) | (103.6M) | (85.7M) | (70.4M) | (48.9M) | (31.3M) | |
(29.2M) | (30.7M) | (33.3M) | (24.9M) | (16.9M) | (10.2M) | (8.7M) | |
(47.8M) | (55.1M) | (56.5M) | (48.4M) | (39.2M) | (24.8M) | (13.2M) | |
-71.5M | -74.5M | -69.4M | -26.6M | -35.6M | -25.6M | -13M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (7K) | (5K) | (0.0) | |
2.7M | 3.1M | 5.1M | 587K | -7K | -5K | 0.0 | |
-8.8M | (15M) | (13.7M) | (12.5M) | (14.2M) | (13.9M) | (9.5M) | |
5.2M | 3.1M | 5.1M | 587K | 1.3M | 1.9M | 0.0 | |
-66.3M | -71.4M | -64.4M | -26.1M | -34.4M | -23.7M | -13M | |
NET INCOME | |||||||
-1.5M | -9.4M | -13.7M | -3.7M | -7.3M | -6.2M | (562K) | |
-64.8M | -62M | -50.6M | -22.3M | -27M | -17.6M | -13.6M |
SEC Filings
OABI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
S-3 S-3 N/A | September 12, 2025 | September 12, 2025 | ||
8-K 8-K 2025 N/A | August 25, 2025 | August 24, 2025 | 2025 |
Related Guides
Continue your OABI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.